PET/MRI Evaluation of Cardiac Amyloid
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/27/2019 |
| Start Date: | May 26, 2016 |
| End Date: | August 2020 |
18F‑Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid
Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called
amyloid in the heart tissue. This makes it difficult for the heart to function properly. The
investigators wish to evaluate if the radiopharmaceutical 18F‑Florbetaben (Neuraceq®) that
targets beta amyloid can also identify cardiac amyloid deposition.
amyloid in the heart tissue. This makes it difficult for the heart to function properly. The
investigators wish to evaluate if the radiopharmaceutical 18F‑Florbetaben (Neuraceq®) that
targets beta amyloid can also identify cardiac amyloid deposition.
The use of hybrid positron emission tomography/ magnetic resonance imaging (PET/MRI) scanners
in clinical practice enhance the ability to evaluate the heart from both an anatomical and
functional perspective. It is hypothesized that an increased PET signal of 18F‑Florbetaben
(Neuraceq®) will be detected in cardiac amyloid deposits within the heart tissue, while the
MRI provides the anatomical information. The ability to reliably and non-invasively image
amyloid deposition in the heart would be potentially advantageous in the following scenarios:
1. Diagnosis of cardiac amyloidosis
2. Decreasing unnecessary invasive myocardial procedures.
The investigators believe this trial will help expand the use of current PET amyloid tracers
and help many patients who currently undergo myocardial biopsy for the diagnosis of cardiac
amyloid.
in clinical practice enhance the ability to evaluate the heart from both an anatomical and
functional perspective. It is hypothesized that an increased PET signal of 18F‑Florbetaben
(Neuraceq®) will be detected in cardiac amyloid deposits within the heart tissue, while the
MRI provides the anatomical information. The ability to reliably and non-invasively image
amyloid deposition in the heart would be potentially advantageous in the following scenarios:
1. Diagnosis of cardiac amyloidosis
2. Decreasing unnecessary invasive myocardial procedures.
The investigators believe this trial will help expand the use of current PET amyloid tracers
and help many patients who currently undergo myocardial biopsy for the diagnosis of cardiac
amyloid.
Inclusion Criteria:
- Patient is ≥ 18 years old at the time of the scan
- Patient with known or suspected cardiac amyloidosis.
- Patient is capable of complying with study procedures
Exclusion Criteria:
- Patient is pregnant or nursing
- Metallic implants (contraindicated for MRI)
- History of renal insufficiency (only for MRI contrast administration)
We found this trial at
1
site
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
Click here to add this to my saved trials
